JOINN Laboratories (China) Co., Ltd. Class H stock analysis
Want to see HK:6127 full AI Analyst Report?
JOINN Laboratories (China) Co., Ltd. Class H (6127) Stock Price & Analysis
6127 Stock Chart & Stats
- Day’s Range
- HKD 23.36 - HKD 25.10
- 52-Week Range
- HKD 15.13 - HKD 32.58
- Previous Close
- HKD 23.94
- Volume
- N/A
- Average Volume (3M)
- 5.76M
- Market Cap
- HKD 37.08B
- Enterprise Value
- HKD 19.66B
- Total Cash (Recent Filing)
- HKD 2.54B
- Total Debt (Recent Filing)
- HKD 37.07M
- Price to Earnings (P/E)
- 29.8
- Beta
- 1.19
- Next Earnings
- Apr 01, 2027 (Est.)
- Last Dividend Ex-Date
- Jun 22, 2026
- Dividend Yield
- 0.58%
Bulls Say, Bears Say
Bulls Say
Strong TTM Profitability
Current profitability is a meaningful strength, with high net, EBIT, and EBITDA margins indicating substantial earnings capacity from the existing operating base. If these margins remain closer to current levels, they can support reinvestment, resilience, and stronger internal funding over the next several quarters.
Very Low Financial Leverage
The exceptionally conservative capital structure gives JOINN considerable financial flexibility. Minimal debt reduces interest and refinancing exposure, preserves capacity to invest in research capabilities, and provides a stronger cushion if client demand or industry conditions weaken over the next two to six months.
Broad CRO Service Relevance
Serving pharmaceutical, biotechnology, and medical device customers gives JOINN exposure to several parts of the healthcare development ecosystem. Its preclinical testing and laboratory work supports safety evaluation and regulatory submissions, making the service offering structurally relevant to clients developing new products.
Bears Say
Uneven Revenue Trajectory
The recent history shows that growth has not been consistently durable, despite a return to approximately 9.9% TTM revenue growth. Earlier declines after rapid expansion make forward performance more dependent on sustained client demand and execution rather than a clearly established multi-year growth pattern.
Weak Earnings-to-cash Conversion
Cash generation is positive and improving, but it is materially below reported earnings. Persistent sub-one-times cash coverage means profits are not yet translating fully into realized cash, which can constrain internally funded investment and makes earnings quality an important consideration for the next several quarters.
Volatile Profitability And Returns
The sharp change in profitability and inconsistent return on equity reduce confidence that current earnings levels will persist unchanged. This volatility makes operating performance the key swing factor, because strong balance-sheet solvency does not by itself ensure stable returns or durable margin performance.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Daniel Gao
- Employees
- 2,649
- Website
- www.joinnlabs.com
- Address
- A5 Rongjing East Street, Beijing, BE, 100176, CN
JOINN Laboratories (China) Co., Ltd. Class H (6127) Earnings & Revenues
6127 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 5 | 0 | 7 |









